Please assess the completion status of the following clinical trial:

Trial Title: CT-011 MAb in DLBCL Patients Following ASCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient's age is 18 years or older, both genders.~2. Confirmed Diffuse Large B-cell Lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with B-cell lineage.~3. The lymphoma is chemosensitive.~4. The lymphoma did not progress since pre-transplant chemotherapy.~5. ECOG performance status 0-1.~Exclusion Criteria:~1. Serious other illness.~2. Active autoimmune disease.~3. Type 1 diabetes.~4. Known immune deficiency.~5. Clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma.~6. Active bacterial, fungal, or viral infection.~7. Positive HIV, Hepatitis B surface antigen plus viremia, or Hepatitis C antibody plus viremia.~8. Pregnant or nursing (positive pregnancy test).~9. Other concurrent clinical study or investigational therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-011 (Type: EXPERIMENTAL): The monoclonal antibody termed CT-011 (currently, pidilizumab).

Based on this trial design, predict the completion outcome and termination type (if applicable).